Intra-Cellular Therapies, Inc.ITCI

Market cap
$13.4B
P/E ratio
Mar 31,
2013
Dec 31,
2013
Dec 31,
2014
Dec 31,
2015
Dec 31,
2016
Dec 31,
2017
Dec 31,
2018
Dec 31,
2019
Dec 31,
2020
Dec 31,
2021
Dec 31,
2022
Dec 31,
2023
Dec 31,
2024
Net loss-------155,127,411-147,722,178-227,005,663-284,125,666-256-140-75
Depreciation-23,24925,481139,626196,872213,872368,673477,121528,1181111
Share-based compensation-391,393411151517212434435364
Stock issued for services--176,085182,599233,772190,885192,530194,205214,103178,534000
Amortization of premiums and accretion of discounts on investment securities, net---297,223-712,675-544,354-429,839943,2391648,2484-089
Accounts receivable, net-35,889-284,715-20,94363,679-94,339--119553952
Inventory--------7891,741162615
Prepaid expenses and other assets-574,341466,0997-4,016,164879,2003-1,465,38481120468
Accounts payable26,1703-1,342,302-419,860228-6,536,036-1,923,19932115
Accrued and other current liabilities--------198,036129837
Accrued customer programs-----------20-28-22
Accrued employee benefits-35-3,873,69221143--247
Lease liabilities, net------------1-0
Net cash used in operating activities-5,930------118,169,113-127,983,241-230,072,845-259,543,485-270-124-73
Purchases of investments--10451439652127181756225759415740
Maturities of investments-237153488429406259276505632521405
Purchases of property and equipment-33,25511,762860,59548,964723,429391,268700,395266,724325,738100
Net cash (used in) provided by investing activities------135177-480,295,000280-128106-335
Proceeds of public offerings, net10,000-116450-162--653-434-543
Proceeds from Stock Options Exercised-332,938162,980653,046477,734285,160674,20631112211824
Net cash provided by financing activities10,000-----685,18836641245518568
Net increase (decrease) in cash, cash equivalents, and restricted cash------1753-46,190,9163257-1159
Income Taxes Paid-31,43744,998-1,000,000-1,6001,6001,6005,631002
Right of use assets under operating leases------------3